CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis: pooled interim results for up to 3 years from the ASSURE study
DOI 10.1055/s-0045-1810647
Bibliografische Angaben
Nachweis in CareLit
Autor:innenE J Lawitz, P J Trivedi, K V Kowdley, S C Gordon, C L Bowlus, M C Londoño Hurtado, G M Hirschfield, A Gulamhusein, M Demir, D B Crittenden, S Zhuo, C Heusner, C Levy
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2025
Jahrgang / SeitenJg. 63 · S. e375-e376
Kernaussage aus der Literatur
Abstract-Vorschau
Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis: pooled interim results for up to 3 years from the ASSURE study
Zitieren
Zitierempfehlung
E J Lawitz, P J Trivedi, K V Kowdley, S C Gordon, C L Bowlus, M C Londoño Hurtado, G M Hirschfield, A Gulamhusein, M Demir, D B Crittenden, S Zhuo, C Heusner, C Levy (2025) Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis: pooled interim results for up to 3 years from the ASSURE study. Zeitschrift für Gastroenterologie, 63 (08), e375-e376. https://doi.org/10.1055/s-0045-1810647
Mit CareLit weiterarbeiten